Join the 'Rebif Rebidose' group to help and get support from people like you.
Rebif Rebidose News
Posted 7 Oct 2015 by Drugs.com
WEDNESDAY, Oct. 7, 2015 – Multiple sclerosis patients taking a new drug experienced fewer relapse rates but more side effects than patients receiving a standard MS therapy, new research indicates. In a trial comparing two sets of more than 900 patients with relapsing-remitting multiple sclerosis, scientists found that those taking the drug daclizumab HYP had a 45 percent lower relapse rate than those taking interferon beta-1a. But patients on the new drug, which has not yet been approved by the U.S. Food and Drug Administration, saw more side effects. Also, they did not experience significantly slower disease progression than those in the interferon beta-1a group over the first several months. "This is one more drug for multiple sclerosis, which is of course very welcome, but it's just one in addition to the 11 or 12 drugs we already have," said Dr. Eugene Lai, a neurologist at Houston ... Read more